Fludarabine treatment favors the retention of miR-485-3p by prostate cancer cells: Implications for survival

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Lucotti, Serena ^a   Rainaldi, Giuseppe ^a,b   Evangelista, Monica ^a   Rizzo, Milena ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

Circulating miRNAs; Drug sensitivity; DU 145 prostate cancer cell line; Exosomes

Indexed keywords

CYCLIN B2; DNA TOPOISOMERASE (ATP HYDROLYSING) A; FLUDARABINE; MICRORNA; MICRORNA 485 3P; NUCLEAR FACTOR Y; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DOWN REGULATION; DRUG SENSITIVITY; EXOSOME; GENETIC ASSOCIATION; IMMUNOBLOTTING; IN VITRO STUDY; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; VIDARABINE;

EID: 84878470989     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-52     Document Type: Article

References (38)

1. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006. 10.1038/cr.2008.282, 18766170.
2. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50:298-301. 10.1016/j.ymeth.2010.01.032, 20146939.
3. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518. 10.1073/pnas.0804549105, 2492472, 18663219.
4. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002, 48:1647-1653.
5. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56:1733-1741. 10.1373/clinchem.2010.147405, 20847327.
6. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010, 9:306. 10.1186/1476-4598-9-306, 3002336, 21110877.
7. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8:467-477. 10.1038/nrclinonc.2011.76, 3423224, 21647195.
8. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3:e3148. 10.1371/journal.pone.0003148, 2519789, 18773077.
9. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011, 80:193-208. 10.1016/j.critrevonc.2010.11.004, 21145252.
10. Steer CJ, Subramanian S. Circulating microRNAs as biomarkers: a new frontier in diagnostics. Liver Transpl 2012, 18:265-269. 10.1002/lt.23377, 22228587.
11. Yu DC, Li QG, Ding XW, Ding YT. Circulating MicroRNAs: Potential Biomarkers for Cancer. Int J Mol Sci 2011, 12:2055-2063. 10.3390/ijms12032055, 3111650, 21673939.
12. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sultmann H. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011, 128:608-616. 10.1002/ijc.25376, 20473869.
13. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012, 106:768-774. 10.1038/bjc.2011.595, 3322952, 22240788.
14. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009, 4:e6229. 10.1371/journal.pone.0006229, 2704963, 19597549.
15. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011, 77(1265):e1216-e1269.
16. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, Gezer U. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 2011, 32:583-588. 10.1007/s13277-011-0154-9, 21274675.
17. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH, Ye DW. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011, 71:326-331. 10.1002/pros.21246, 20842666.
18. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol 1990, 17:3-17.
19. Patella F, Lucotti S, Rizzo M, Evangelista M, Rainaldi G. The RNA activator ds-p21 potentiates the cytotoxicity induced by fludarabine in Dohh2 cells. Oligonucleotides 2011, 21:39-45. 10.1089/oli.2010.0249, 21241187.
20. Chen CF, He X, Arslan AD, Mo YY, Reinhold WC, Pommier Y, Beck WT. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIalpha and drug responsiveness. Mol Pharmacol 2011, 79:735-741. 10.1124/mol.110.069633, 3063729, 21252292.
21. Imbriano C, Gurtner A, Cocchiarella F, Di Agostino S, Basile V, Gostissa M, Dobbelstein M, Del Sal G, Piaggio G, Mantovani R. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol 2005, 25:3737-3751. 10.1128/MCB.25.9.3737-3751.2005, 1084283, 15831478.
22. Jin S, Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 1998, 18:4377-4384. 109021, 9632821.
23. Redis RS, Calin S, Yang Y, You MJ, Calin GA. Cell-to-cell miRNA transfer: From body homeostasis to therapy. Pharmacol Ther 2012, 136:169-174. 10.1016/j.pharmthera.2012.08.003, 22903157.
24. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics 2010, 73:1907-1920. 10.1016/j.jprot.2010.06.006, 20601276.
25. Simpson RJ, Jensen SS, Lim JW. Proteomic profiling of exosomes: current perspectives. Proteomics 2008, 8:4083-4099. 10.1002/pmic.200800109, 18780348.
26. Record M, Subra C, Silvente-Poirot S, Poirot M. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem Pharmacol 2011, 81:1171-1182. 10.1016/j.bcp.2011.02.011, 21371441.
27. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659. 10.1038/ncb1596, 17486113.
28. Zhuang X, Sun D, Zhang S, Deng ZB, Grizzle W. Miller D 2012, Zhang HG: Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv Drug Deliv Rev.
29. Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 2009, 9:244. 10.1186/1471-2407-9-244, 2719664, 19619303.
30. Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, Alevizos I. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis 2010, 16:34-38. 10.1111/j.1601-0825.2009.01604.x, 2844919, 19627513.
31. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009, 10:42-46. 10.3816/CLC.2009.n.006, 19289371.
32. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008, 110:13-21. 10.1016/j.ygyno.2008.04.033, 18589210.
33. Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth J, Mason MD, Clayton A. Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics 2010, 9:1324-1338. 10.1074/mcp.M000063-MCP201, 2877990, 20224111.
34. Silva J, Garcia V, Zaballos A, Provencio M, Lombardia L, Almonacid L, Garcia JM, Dominguez G, Pena C, Diaz R, et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J 2011, 37:617-623. 10.1183/09031936.00029610, 20595154.
35. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, Ju S, Mu J, Zhang L, Steinman L, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 2011, 19:1769-1779. 10.1038/mt.2011.164, 3188748, 21915101.
36. Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S, Thomas-Tikhonenko A. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 2011, 30:2587-2594. 10.1038/onc.2010.634, 3128883, 21297663.
37. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010, 38:7248-7259. 10.1093/nar/gkq601, 2978372, 20615901.
38. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010, 39:133-144. 10.1016/j.molcel.2010.06.010, 20603081.